Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018

Background. Clostridioides difficile (CDI) is the most common cause of nosocomial diarrheal infections. Historically, metronidazole was the first-line treatment, but guidelines now indicate oral vancomycin and fidaxomicin as primary antibiotics for initial episodes. A provincial stewardship program...

Full description

Bibliographic Details
Main Authors: Ariana Saatchi, Sungeun Kim, Fawziah Marra
Format: Article
Language:English
Published: Hindawi Limited 2023-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2023/9465158
_version_ 1797903015281164288
author Ariana Saatchi
Sungeun Kim
Fawziah Marra
author_facet Ariana Saatchi
Sungeun Kim
Fawziah Marra
author_sort Ariana Saatchi
collection DOAJ
description Background. Clostridioides difficile (CDI) is the most common cause of nosocomial diarrheal infections. Historically, metronidazole was the first-line treatment, but guidelines now indicate oral vancomycin and fidaxomicin as primary antibiotics for initial episodes. A provincial stewardship program has operated in British Columbia (BC), since 2005. Since the program's inception, surveillance of antibiotic use has been ongoing. However, this is the first study to review community-acquired CDI-indicated antibiotic use. Moreover, this study offers the first interpretation of fidaxomicin use in BC since its addition to the provincial formulary. Methods. A retrospective cohort analysis included all outpatient dispensations for CDI-related antibiotics from January 1, 2000, to December 31, 2018. Antibiotic dispensations were extracted for metronidazole, vancomycin, and fidaxomicin. Consumption rates were calculated as prescriptions per 1000 population. Rates were examined overall and then stratified by medication, age, and sex. Secondary outcomes of interest included an examination of adherence to provincial special authority criteria; and proportions of outpatient antibiotic use attributable to administrative health records for CDI. Results. The average annual rate of prescribing was 18.5 per 1000 population for all CDI-indicated antibiotics. The rate of prescribing increased (15%) over the 19-year study period, from 17.2 to 19.8 dispensations per 1000 population. Metronidazole accounted for the most antibiotics dispensed in every study year; however, by 2018 it demonstrated the most modest increase in use (15%). In comparison, fidaxomicin increased by 226% by 2018. Vancomycin had the highest percentage increase (621%), with the greatest change occurring from 2014 to 2015, correlating to the dissemination of new clinical practice guidelines. Conclusion. This is the first study to evaluate outpatient prescribing for CDI-indicated antibiotics, and one of the few studies to examine fidaxomicin since its introduction to Canadian formularies. Although causation cannot be inferred from study results, oral vancomycin, and fidaxomicin use has increased in line with, or in advance-of guidelines.
first_indexed 2024-04-10T09:26:17Z
format Article
id doaj.art-340c461a0b9d49aa99071d966460c8aa
institution Directory Open Access Journal
issn 1918-1493
language English
last_indexed 2024-04-10T09:26:17Z
publishDate 2023-01-01
publisher Hindawi Limited
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj.art-340c461a0b9d49aa99071d966460c8aa2023-02-20T01:57:33ZengHindawi LimitedCanadian Journal of Infectious Diseases and Medical Microbiology1918-14932023-01-01202310.1155/2023/9465158Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018Ariana Saatchi0Sungeun Kim1Fawziah Marra2Faculty of Pharmaceutical SciencesFaculty of Pharmaceutical SciencesFaculty of Pharmaceutical SciencesBackground. Clostridioides difficile (CDI) is the most common cause of nosocomial diarrheal infections. Historically, metronidazole was the first-line treatment, but guidelines now indicate oral vancomycin and fidaxomicin as primary antibiotics for initial episodes. A provincial stewardship program has operated in British Columbia (BC), since 2005. Since the program's inception, surveillance of antibiotic use has been ongoing. However, this is the first study to review community-acquired CDI-indicated antibiotic use. Moreover, this study offers the first interpretation of fidaxomicin use in BC since its addition to the provincial formulary. Methods. A retrospective cohort analysis included all outpatient dispensations for CDI-related antibiotics from January 1, 2000, to December 31, 2018. Antibiotic dispensations were extracted for metronidazole, vancomycin, and fidaxomicin. Consumption rates were calculated as prescriptions per 1000 population. Rates were examined overall and then stratified by medication, age, and sex. Secondary outcomes of interest included an examination of adherence to provincial special authority criteria; and proportions of outpatient antibiotic use attributable to administrative health records for CDI. Results. The average annual rate of prescribing was 18.5 per 1000 population for all CDI-indicated antibiotics. The rate of prescribing increased (15%) over the 19-year study period, from 17.2 to 19.8 dispensations per 1000 population. Metronidazole accounted for the most antibiotics dispensed in every study year; however, by 2018 it demonstrated the most modest increase in use (15%). In comparison, fidaxomicin increased by 226% by 2018. Vancomycin had the highest percentage increase (621%), with the greatest change occurring from 2014 to 2015, correlating to the dissemination of new clinical practice guidelines. Conclusion. This is the first study to evaluate outpatient prescribing for CDI-indicated antibiotics, and one of the few studies to examine fidaxomicin since its introduction to Canadian formularies. Although causation cannot be inferred from study results, oral vancomycin, and fidaxomicin use has increased in line with, or in advance-of guidelines.http://dx.doi.org/10.1155/2023/9465158
spellingShingle Ariana Saatchi
Sungeun Kim
Fawziah Marra
Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018
Canadian Journal of Infectious Diseases and Medical Microbiology
title Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018
title_full Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018
title_fullStr Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018
title_full_unstemmed Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018
title_short Retrospective Cohort Analysis of Outpatient Antibiotic Use for Clostridioides difficile-Indicated Agents in British Columbia, from 2000 to 2018
title_sort retrospective cohort analysis of outpatient antibiotic use for clostridioides difficile indicated agents in british columbia from 2000 to 2018
url http://dx.doi.org/10.1155/2023/9465158
work_keys_str_mv AT arianasaatchi retrospectivecohortanalysisofoutpatientantibioticuseforclostridioidesdifficileindicatedagentsinbritishcolumbiafrom2000to2018
AT sungeunkim retrospectivecohortanalysisofoutpatientantibioticuseforclostridioidesdifficileindicatedagentsinbritishcolumbiafrom2000to2018
AT fawziahmarra retrospectivecohortanalysisofoutpatientantibioticuseforclostridioidesdifficileindicatedagentsinbritishcolumbiafrom2000to2018